Results 71 to 80 of about 5,265 (145)

Enterovirus infections in children

Pediatric Investigation, Volume 10, Issue 5, Page 409-431, October 2026.
Enteroviruses (EVs) are major pathogens causing a wide spectrum of diseases in children worldwide. This review summarizes the epidemiology, virology, viral replication, and virus‐host interactions of EVs. It also highlights current advances in clinical diagnosis, antiviral therapies, and vaccine development, providing insights into future strategies ...
Xiangpeng Chen, Lingyun Guo, Xiaobo Lei, Linqing Zhao, Mingyan Hei, Jun Shen, Ju Yin, Fei Li, Jikui Deng, Gang Liu, Yong Zhang, Zhengde Xie   +11 more
wiley   +1 more source

Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C

, 2018
Compliance with Ethical StandardsFunding: The preparation of this review was not supported by any external funding.Conflicts of interest: Young-A Heo and Emma Deeks are salaried employees of Adis/Springer, are responsible for the article content and ...
Young-A Heo (4077493), Emma D. Deeks (4985339)   +1 more
core   +1 more source

Method development and validation of Sofosbuvir and iedipasvirin by HPLC: A Review [PDF]

, 2019
The aim of this review article is emphasizing on development and validation protocol which will used to develop and validate accurate, simple, selective and specific spectrophotometric methods for the determination of Sofosbuvir (SOF) and Ledipasvir (LDV)
Kunjir, Vaibhavi Vasant, Shete, Rajkumar V., Vidhate, Sagar Ramdas   +2 more
core   +1 more source

Sofosbuvir-Based Therapy for Genotype 4 HCV Recurrence Post-Liver Transplant Treatment-Experienced Patients

Canadian Journal of Gastroenterology and Hepatology, 2016
Background and Aim. This is an open label prospective cohort study conducted at a tertiary care hospital. The primary endpoint is SVR12 in patients treated with sofosbuvir-based therapy in post-liver transplant patients with genotype 4 HCV recurrence ...
A. Ajlan, A. Al-Jedai, H. Elsiesy, D. Alkortas, W. Al-Hamoudi, R. Alarieh, M. Al-Sebayel, D. Broering, F. Aba Alkhail   +8 more
doaj   +1 more source

Development of a Machine Learning Model to Predict Short Duration HCV Treatment Response

Journal of Viral Hepatitis, Volume 33, Issue 10, October 2026.
ABSTRACT Standard durations of direct acting antivirals (DAAs; 8–12 weeks) can be a barrier to HCV treatment initiation and completion among marginalized populations. This study developed and internally validated a machine learning model to predict short‐duration (4–6 weeks) DAA response using baseline clinical factors with potential to improve ...
Joanne M. Carson, Sebastiano Barbieri, Andrey Verich, Elise Tu, Andrew Lloyd, Gregory J. Dore, Gail V. Matthews, Marianne Martinello   +7 more
wiley   +1 more source

Combination ledipasvir-sofosbuvir for the treatment of chronic hepatitis C virus infection: a review and clinical perspective

, 2016
Marcel Nkuize,1 Thomas Sersté,1,2 Michel Buset,1 Jean-Pierre Mulkay11Department of Gastroenterology and Hepatology, Saint-Pierre University Hospital, 2Department of Gastroenterology, Pancreatology and Hepatology, Hôpital Academique Erasme ...
Sersté T, Mulkay JP, Nkuize M, Buset M
core  

The reasons for the discontinuation of sofosbuvir/lediprevir.

, 2018
The reasons for the discontinuation of sofosbuvir/lediprevir.
Takeshi Kure (5328974), Tsutomu Tamai (496424), Kazuaki Tabu (496423), Kohei Oda (496422), Takeshi Hori (166759), Akihiro Moriuchi (496425), Masafumi Hashiguchi (5328965), Yukiko Inada (5328971), Kotaro Kumagai (496421), Hirofumi Uto (496418), Yasunari Hiramine (5328956), Seiichi Mawatari (496417), Kunio Fujisaki (5328962), Oki Taniyama (5328968), Sho Ijuin (5328953), Akio Ido (496419), Ai Kasai (5328959)   +16 more
core   +1 more source

Sex Disparities in Hepatitis C Treatment Initiation: Role of Universal Access to DAA in France (ANRS FANTASIO 2)

Liver International, Volume 46, Issue 10, October 2026.
ABSTRACT Background and Aims Ensuring access to direct‐acting antivirals (DAA) for all individuals concerned is a priority in hepatitis C elimination efforts. We analysed sex disparities in DAA initiation in France over a 9‐year period spanning before and after August 2017, when the country implemented universal DAA access.
Fabienne Marcellin, Clémence Ramier, Cécile Brouard, Vincent Di Beo, Yoann Allier, Abbas Mourad, Morgane Bureau‐Stoltmann, Philippe Sogni, Sylvie Deuffic‐Burban, Patrizia Carrieri, Benjamin Rolland, Marc Bourliere, Camelia Protopopescu   +12 more
wiley   +1 more source

Whole‐Genome Analysis of HEV Under Sequential Ribavirin Pressure Reveals Early Minor Variants Predicting Resistance

Journal of Medical Virology, Volume 98, Issue 9, September 2026.
ABSTRACT Ribavirin (RBV) failures in chronic hepatitis E virus (HEV) infection may arise from genomic adaptation, yet the contribution of minor variants remains insufficiently explored. Using a shotgun metagenomics based on next‐generation sequencing to obtain the full HEV genome, we analyzed longitudinal HEV populations from sequential clinical ...
Sergi Colomer‐Castell, Marta Ibañez‐Lligoña, Carolina Campos, Josep Gregori, Damir Garcia‐Cehic, Ariadna Rando‐Segura, Roser Ferrer, Sofía P. Ruzo, Maria Francesca Cortese, David Tabernero, Judit Vico‐Romero, Juan Carlos Ruiz‐Cobo, Maria Buti, Mar Riveiro‐Barciela, Josep Quer   +14 more
wiley   +1 more source

Additional file 3 of Effect of sofosbuvir-based DAAs on changes in lower-density lipoprotein in HCV patients: a systematic review and meta-analysis

, 2021
Additional file 3: Fig. S3. Chemicalstructures of tenofovir alafenamide, sofosbuvir, and tenofovir disoproxilfumarate.
Ming-Chih Hou (383484), Ying-Wen Wang (404816), Wei-Ping Lee (11464170), Yi-Hsiang Huang (115190), Keng-Hsin Lan (449370)   +4 more
core   +1 more source